Osimertinib Tablets

Get a Price/Quote

MOQ : 100 Packs

Osimertinib Tablets Specification

Salt Composition
Osimertinib mesylate

Origin of Medicine
India

Packaging Type
Box

Dosage Form
Solid oral dosage form

Indication
Treatment of locally advanced or metastatic NSCLC with EGFR T790M mutation

Brand Name
Tagrisso (Osimertinib)

Life Span
24 months from date of manufacture

Pacakaging (Quantity Per Box)
30 tablets

Drug Type
Targeted therapy, prescription only

Ingredients
Osimertinib

Physical Form
Tablets

Function
EGFR-TKI, anticancer therapy

Recommended For
Non-Small Cell Lung Cancer (NSCLC) patients with specific EGFR mutations

Dosage
As prescribed by a healthcare professional

Dosage Guidelines
Take once daily, with or without food

Suitable For
Adults

Quantity
30 tablets per box

Storage Instructions
Store below 30C, protect from moisture and light

Prescription Status
Prescription required

Pregnancy Category
Not recommended during pregnancy or breastfeeding

Monitoring Requirements
Monitor for interstitial lung disease (ILD), cardiotoxicity, and QT prolongation

ATC Code
L01EB04

Appearance
Film-coated, round tablets

Side Effects
Diarrhea, rash, dry skin, nail toxicity, stomatitis, decreased appetite

Strength
80 mg per tablet

Contraindications
Hypersensitivity to Osimertinib or any excipients

Approval
US FDA, EMA, and other regulatory agencies

Patient Counselling Information
Do not crush, split, or chew the tablet. Adhere to prescribed dosing schedule.

Route of Administration
Oral

Osimertinib Tablets Trade Information

Minimum Order Quantity
100 Packs

Payment Terms
Cash in Advance (CID)

Supply Ability
5000 Packs Per Month

Delivery Time
10 Days

Main Domestic Market
All India

About Osimertinib Tablets

Explore the valiant strength and optimum efficacy of Tagrisso (Osimertinib) Tablets, available at a special reduced price. Designed as film-coated, round tablets with a robust 80 mg per tablet, this kingly formulation is an EGFR-TKI targeted therapy used in adults for the treatment of non-small cell lung cancer (NSCLC) with specific EGFR T790M mutations. Approved by US FDA, EMA, and leading global regulatory agencies, Tagrisso ensures precision-driven cancer care. Adhere to prescribed dosing, and consult your healthcare provider for comprehensive safety monitoring and patient counseling.

Special Features and Commercial Applications

Osimertinib Tablets boast a film-coated, round structure, offering targeted action in NSCLC patients with EGFR T790M mutations. This prescription-only, kingly anticancer therapy is administered orally for optimum patient convenience. Special features include a robust safety profile and 24-month shelf life. Commercial uses primarily cover the treatment of locally advanced or metastatic NSCLC. The application surface involves oral administration once daily, with or without food, directly supporting advanced cancer management.

Export Market Reach and Delivery Expertise

Osimertinib Tablets are widely recognized in international export markets, thanks to diligent transport services and secure packaging. With India as the main domestic market, suppliers ensure that deliveries arrive on time, securely boxed with 30 tablets per package. Export markets span multiple regions where quality anticancer agents are in demand. Our robust packaging and expedited transport services make us a preferred choice for both local and international buyers seeking reliability and prompt delivery.

FAQ's of Osimertinib Tablets:

Q: How should Osimertinib Tablets be taken for optimal effectiveness?

A: Osimertinib Tablets should be taken exactly as prescribed by your healthcare provider, once daily, with or without food. Do not crush, split, or chew the tablets.

Q: What are the special benefits of choosing Tagrisso (Osimertinib) for NSCLC patients?

A: Tagrisso offers targeted therapy for NSCLC patients with EGFR T790M mutations, providing advanced, valiant action and kingly results, with approvals from global regulatory agencies.

Q: When should monitoring occur during the usage of Osimertinib Tablets?

A: Healthcare providers should monitor for signs of interstitial lung disease (ILD), cardiotoxicity, and QT prolongation throughout the treatment process to ensure patient safety.

Q: Where can Osimertinib Tablets be supplied from?

A: Our supply originates from India, with capabilities for commercial export and efficient delivery to many international markets, as well as across the main domestic market.

Q: What precautions must patients observe while using Osimertinib Tablets?

A: Patients must not use the tablets if allergic to Osimertinib or its excipients, should avoid use during pregnancy or breastfeeding, and must adhere strictly to prescribed dosing guidelines.

Tell us about your requirement